MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ehjqcco/qcag074

Медицинская библиотека · European heart journal. Quality of care & clinical outcomes · 2026

Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study.

Debonnaire Philippe, L'Hoyes Wouter, Dujardin Karl, Donal Erwan, Verheyen Nicolas, Dupont Matthias, De Sutter Johan, Timmermans Philippe, Pouleur Anne-Catherine, Droogmans Steven, Issa Victor Sarli, Dulgheru Raluca, Regeer Madelien, Jurcut Ruxandra, Bondue Antoine, Bohyn Alexandre, Bogaerts Kris, Christiaen Emma, Wyseure Nicolas, Bezard Mélanie, Zach David, Schwegel Nora, Knapen Robbe, Buytaert Lars, de Marneffe Nils, Ajmone Marsan Nina, Adam Robert, Tavernier René, Buysschaert Ian, Trenson Sander

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

AIMS: The natural history and response to tafamidis treatment in women with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) remain insufficiently characterized. Current study aimed to explore sex-differences in clinical presentation, natural course, and tafamidis treatment efficacy, focusing on women with ATTRwt-CM.

METHODS AND

RESULTS

An international, multicentric cohort of ATTRwt-CM subjects was evaluated, including for all-cause mortality. In total, 1454 patients were studied (mean age 81 ± 7y), including 307 (21.1%) females. At presentation, females were ∼3 years older than males with slightly worse phenotype, including higher indexed left ventricular wall thickness and National Amyloidosis Centre (NAC) disease stage (P < 0.050). Heart failure with preserved ejection fraction and hypertension coincided more often in women (P = 0.001). Natural disease course was poor without sex-difference, even when age-corrected (P = 0.210). Tafamidis was initiated in 1055 patients, 12% less in females (P < 0.001), although reasons for non-initiation and discontinuation did not show heterogeneity by sex (P = 0.116 and P = 0.304, respectively), indicating structural undertreatment. After 1.9 (0.9-3.3) years of median follow-up, 409 (28.1%) patients died. Tafamidis related to lower mortality in the overall and propensity score-matched cohort (n = 742, HR 0.44, 95% CI 0.32-0.61, P < 0.001), without sex-difference (female HR 0.76, 95% CI 0.52-1.11, P = 0.150) nor sex-based treatment efficacy interaction (P = 0.381). NAC disease stages strongly related to mortality under tafamidis treatment (HR 2.13%, 95%, 1.81-2.50, P < 0.001), but female sex did not (HR 0.82, 95% CI 0.53-1.27, P = 0.365).

CONCLUSION

Women with ATTRwt-CM are prone to underdiagnosis and undertreatment, despite similar poor natural course and tafamidis treatment efficacy. Initiatives to increase diagnostic awareness and disease modifying treatment initiation in women are urgently needed.

Для цитирования: Debonnaire Philippe, L'Hoyes Wouter, Dujardin Karl, Donal Erwan, Verheyen Nicolas, Dupont Matthias, De Sutter Johan, Timmermans Philippe, Pouleur Anne-Catherine, Droogmans Steven, Issa Victor Sarli, Dulgheru Raluca, Regeer Madelien, Jurcut Ruxandra, Bondue Antoine, Bohyn Alexandre, Bogaerts Kris, Christiaen Emma, Wyseure Nicolas, Bezard Mélanie, Zach David, Schwegel Nora, Knapen Robbe, Buytaert Lars, de Marneffe Nils, Ajmone Marsan Nina, Adam Robert, Tavernier René, Buysschaert Ian, Trenson Sander. Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study.. European heart journal. Quality of care & clinical outcomes. 2026. DOI: 10.1093/ehjqcco/qcag074.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.